Buelow R, van Schooten W
Therapeutic Human Polyclonals Inc., 2105 Landings Drive, 94043, Mountain View, USA.
Ernst Schering Found Symp Proc. 2006(4):83-106. doi: 10.1007/2789_2007_040.
Antibodies have been used successfully as therapeutics for over 100 years. The successful development of therapeutic human(ized) monoclonal antibodies (mAbs) in the last 20 years has demonstrated the potency of mAbs but also revealed some of their limitations. Studies in animals and humans demonstrated that it is possible to overcome some of these limitations using mixtures of mAbs or polyclonal antibody (pAb) preparations. pAbs from human and animal plasma are efficacious and safe therapeutics for the treatment of many diseases. Novel technologies are being developed for the production of human pAbs in genetically engineered animals. Immunization of such animals should allow the production of effective and safe high-titer antibody preparations for the treatment of infectious diseases, cancer, and autoimmunity.
抗体作为治疗药物已成功应用了100多年。过去20年中治疗性人源（化）单克隆抗体（mAb）的成功开发证明了mAb的效力，但也揭示了它们的一些局限性。在动物和人类身上进行的研究表明，使用mAb混合物或多克隆抗体（pAb）制剂有可能克服其中一些局限性。来自人和动物血浆的pAb是治疗许多疾病的有效且安全的治疗药物。正在开发用于在基因工程动物中生产人源pAb的新技术。对这类动物进行免疫接种应能生产出用于治疗传染病、癌症和自身免疫性疾病的有效且安全的高滴度抗体制剂。
